| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5595801 | The American Journal of the Medical Sciences | 2017 | 23 Pages |
Abstract
The NCCN-IPI is a clinically useful prognostic index for patients with DLBCL treated in the rituximab era, especially for high-risk patients.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Yan MD, Lanlan MD, Yanna MD, Tingting MD, Mei PhD,